DMTK

About DermTech, Inc.

DermTech, Inc., a molecular diagnostics firm headquartered in La Jolla, California, specializes in creating and bringing to market advanced, non-invasive genomic tests. Operating within the United States, their innovative solutions facilitate the diagnosis of various dermatological issues, including skin cancer, inflammatory conditions, and age-related skin concerns. A cornerstone of their offerings is the DermTech Melanoma Test (DMT), a sophisticated gene expression analysis. This assay plays a crucial role in enhancing the early identification of genomic abnormalities, effectively aiding in the exclusion of melanoma and often removing the need for invasive surgical biopsies of suspicious pigmented lesions. The company further provides specialized adhesive kits for convenient skin sample collection. Additionally, they offer gene expression assays designed to analyze key inflammatory pathways such, as Th1, Th2, IFN-gamma, and Th17. Looking ahead, DermTech is actively developing a pipeline of new products, which includes DNA risk assessment tools for UV damage, diagnostic tests for non-melanoma skin cancers, and rule-out tests for cutaneous T-cell lymphoma. They also extend their services by delivering health-related information and support through digital and telecommunication platforms. DermTech's diagnostic products and services are primarily targeted towards medical professionals in the fields of pathology and oncology.

CEO: Bret Christensen
IPO Date: Aug 10, 2017

Market Data

Open: $0.099
High: $0.1002
Low: $0.089
Volume: 3.4M
52W High: $3.90
52W Low: $0.044

Valuation

Market Cap: $3.3M
Enterprise Value: $17.7M

Financials

Free Cash Flow: -$77.9M
Revenue: $15.3M
Net Income: -$100.9M
Cash: $36.7M
Debt: $54.4M

Events

EarningsAug 1

EPS est. -0.52 · actual -0.99